Product development pipeline

LAS190792: Dual long-acting Muscarinic Antagonist β2 Agonist (MABA), which combines two bronchodilator mechanisms in a single molecule for the treatment of COPD.

Aclidinium bromide monotherapy: Anticholinergic bronchodilator, selective M3 muscarinic antagonist for the treatment of COPD currently in phase III clinical development. Aclidinium bromide is a long acting drug, with a very clean safety profile, and administered by inhalation through a user-friendly multidose inhaler device, which is also proprietary to Almirall.

Combination of aclidinium bromide with the long acting beta agonist formoterol (LAS40464): Treatment with one or more long acting bronchodilators is recommended by the international guidelines for treatment of COPD. This combination is aimed at providing higher efficacy than each component alone, as well as the improved convenience of having the two products in the same easy to use inhalation device. LAS40464 is currently in phase II clinical development.

LAS100977: Long acting beta agonist inhaled bronchodilator for the treatment of asthma and COPD which is in phase IIa of clinical development. Results obtained in asthmatic patients showed that LAS100977 is a potent bronchodilator, with duration of action compatible with once daily dosing.

LAS186323: DHODH inhibitor for the oral treatment of rheumatoid arthritis that aims at reducing the undesirable side effects of the DHODH inhibitor commercially available at present. . This is currently in phase I clinical trials. Almirall is currently exploring partnership options.

Sativex® -basically, a combination of two cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD)- is formulated as an oromucosal spray which is administered by spraying into the mouth. Each spray of Sativex delivers a fixed dose of 2.7mg THC and 2.5mg CBD.

Currently in Phase III.

LAS189913: Sphingosine-1-phosphate-1 (S1P1) receptor agonist for the oral treatment of multiple sclerosis, that aims to reduce undesirable side effects of other S1P1 agonists through an improved pharmacokinetic and safety profile. Almirall's S1P1 agonist is currently in preclinical development. Almirall is currently exploring partnership options.

LAS 41002: Topical anti-inflammatory agent for the treatment of eczema, which is in clinical phase III in comparison studies with Ecural. LAS41002 acts on a corticosteroid receptor and its different formulations will allow treatment of different skin conditions.

LAS41004: This compound is in phase II, the goal is to confirm its anti-inflammatory activity and its capacity to inhibit cellular proliferation through topical administration for the treatment of psoriasis and/or atopic dermatitis.

Linaclotide is a first-in-class medicine for the treatment of irritable bowel syndrome with constipation (IBS-C). It is a once daily, orally delivered peptide that acts locally in the gut with no detectable systemic exposure at therapeutic doses. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine.

Irritable bowel syndrome with constipation (IBS-C) is a chronic functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with altered bowel habits. There are currently few available therapies to treat this disorder. An estimated nine million patients in Europe suffer from IBS-C. Patients can be affected physically, psychologically, socially, and economically.